Analyzing Pacific Biosciences of California (NASDAQ:PACB) & NexGel (NASDAQ:NXGL)

NexGel (NASDAQ:NXGL) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Profitability

This table compares NexGel and Pacific Biosciences of California’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexGel	-24.69%	-47.35%	-24.67%
Pacific Biosciences of California	-341.47%	-326.43%	-19.40%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NexGel and Pacific Biosciences of California, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1	0	0	0	1.00
Pacific Biosciences of California	1	2	3	1	2.57

Pacific Biosciences of California has a consensus target price of $2.20, indicating a potential upside of 35.80%. Given Pacific Biosciences of California’s stronger consensus rating and higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than NexGel.

Earnings & Valuation

This table compares NexGel and Pacific Biosciences of California”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexGel	$8.69 million	1.06	-$3.28 million	($0.37)	-3.05
Pacific Biosciences of California	$160.01 million	3.06	-$546.38 million	($1.84)	-0.88

NexGel has higher earnings, but lower revenue than Pacific Biosciences of California. NexGel is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

2.2% of NexGel shares are held by institutional investors. 20.6% of NexGel shares are held by insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

NexGel has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500.

Summary

Pacific Biosciences of California beats NexGel on 9 of the 15 factors compared between the two stocks.

About NexGel

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.